<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2539">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03073837</url>
  </required_header>
  <id_info>
    <org_study_id>500-16-0006</org_study_id>
    <nct_id>NCT03073837</nct_id>
  </id_info>
  <brief_title>Rudolph: Nasal Microbiota With Red and Sore Nose</brief_title>
  <official_title>RUDOLPH Study Nasal Microbiota and Concurrent Nose Soreness Associated With Common Cold Infection - a Pilot Using the HRV-16 Challenge Model in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kimberly-Clark Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NIZO Food Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kimberly-Clark Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot study will utilize the experimental rhinovirus infection model to study changes
      in skin microbiota in relation to skin erythema and soreness.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">March 20, 2017</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>nasal microbiota composition and occurrence of nose redness and soreness during rhinovirus infection</measure>
    <time_frame>change from baseline compared to day 22</time_frame>
    <description>Taxonomic classification of bacterial strains before and after HRV-16 virus for subjects with a VAS score rating &gt;37mm</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Dermatitis</condition>
  <arm_group>
    <arm_group_label>Rhinovirus Challenge</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Challenge with HRV-16</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Rhinovirus Challenge</intervention_name>
    <description>Challenge with HRV-16 virus</description>
    <arm_group_label>Rhinovirus Challenge</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  self reported proneness to developing symptoms of nose redness and/or soreness

          -  sero-negative to HRV-16 at screening

        Exclusion Criteria:

          -  confirmed or self-reported allergic rhinitis

          -  history of nasal or otologic surgery

          -  use of anti-inflammatory medication, recent antibiotics or anti-histamines
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lutter Rene, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AIDS Malignancy Consortium</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alwine Kardinaal</last_name>
    <phone>+31 318 659 585</phone>
    <email>Alwine.Kardinaal@nizo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rene Lutter</last_name>
      <phone>+31-205668753</phone>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 16, 2017</lastchanged_date>
  <firstreceived_date>February 21, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dermatitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
